Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138775 | Leukemia Research | 2006 | 4 Pages |
Abstract
Advanced-phase chronic myeloid leukemia patients treated with imatinib often relapse due to point mutations in the Abl kinase domain. We herein examine the in vitro and in vivo effects of a Bcr-Abl/Lyn dual tyrosine kinase inhibitor, NS-187, on seven mutated Bcr-Abl proteins. NS-187 inhibited both Tyr393-phosphorylated and Tyr393-unphosphorylated Abl, resulting in significant in vitro growth inhibition of cells expressing six of seven mutated Bcr-Abl kinases, though not T315I. Furthermore, NS-187 prolonged the survival of mice injected with leukemic cells expressing all mutated Bcr-Abl tested except T315I, and its efficacy correlated well with its in vitro effects.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Haruna Naito, Shinya Kimura, Yohei Nakaya, Haruna Naruoka, Sachie Kimura, Shinsaku Ito, Tatsushi Wakayama, Taira Maekawa, Kazuko Hirabayashi,